Daiichi Sankyo
Daiichi Sankyo

Bioprocessing Breakthroughs: Experts Share Insights!
🌟 Experts dive into bioprocessing challenges, AI's impact, and networking at BPI. Discover trends shaping a dynamic future! 🤖🤝🔗

Revolutionizing Pharma: AI Learns from Experts!
🤖 AI is revolutionizing cell therapy! Multiply Labs and Stanford's LCGM use imitation learning to automate procedures and enhance efficiency. 💊🔬

Capra Biosciences wins $75M to solve pharmaceutical shortages
🔍 Capra Biosciences awarded $7.5M project to scale and manufacture bio-derived small-molecule APIs, addressing ingredient shortages. 🧪🌱🚀

Revolutionary Microfluidics: The Future of Personalized Medicine
🧪 Microfluidics + 🔬 = 💰 & 💉. Discover how personalized medicine can benefit from this powerful combination.

Unlocking Advanced Therapy’s Potential with AI: The Key Ingredients
🌍 Advanced therapy manufacturers must have robust hardware and monitoring software in place before benefiting from AI. 🤖📈

Revolutionary Alliance Launches AI-Driven Eye Therapy
👀 Three companies join forces to develop gene therapy for eye diseases, using AI and machine learning algorithms. 🧬👁️🔬

Robots and AI Revolutionize Cell and Gene Therapy Manufacturing!
🤖🔬 Researchers suggest that robots and AI can address manufacturing challenges in cell and gene therapy. ⬆️🌍 The industry is growing rapidly, requiring skilled personnel and increased production. 🤖🔬 Automation and AI can improve efficiency and reduce costs.

Revolutionizing Therapy Development with ExoXpert: Harnessing the Power of Exosomes
🌟 Introducing ExoXpert: A game-changing contract development and manufacturing organization for exosome-based therapies! 🚀 ExosomeTherapies CuttingEdgeTech

Daiichi Sankyo Skyrockets Oncology Power with $1bn Expansion
🔬💰 Daiichi Sankyo expands its oncology portfolio with a $1bn investment, strengthening their position in the industry. 🏥🚀


